SQ109 Inhibitor

Solid. Powder

98.00%

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

330.55

DMSO: 25mg/mL (75.63mM)
(<1mg/ml refers to the product slightly soluble or insoluble)

C22H38N2

C/C(C)=C/CC/C(C)=C/CNCCNC1[C@H]2C[C@H]3C[C@@H]1C[C@H](C3)C2

502487-67-4

trypomastigote cell: ic50 50+/-8nM

SQ109 (0.1-25mg/kg per day, p.o., mice for 28 days) causes dose-dependent reductions of mycobacterial load in both spleen and lung comparable to that of EMB administered at 100mg/kg per day but is less potent than isoniazid at 25mg/kg per day. Pharmacokinetic profiles of SQ109 in mice following a single administration showed its Cmax as 1038 (i.v.) and 135ng/mL (p.o.), with an oral Tmax of 0.31 hours. The elimination t1/2 of SQ109 is 3.5 (i.v.) and 5.2 h (p.o.). The oral bioavailability is 4%. The terminal half-life (t1/2) of SQ109 in dogs (12-29 hours, mean 29.3 hours) is longer than in rats (7-8 h, mean 7.4 h), as reflected by the significantly larger volume of distribution of SQ109 in dogs. The oral bioavailability of SQ109 in rats and dogs is determined to be 12% and 5%, respectively [2][3].